Nutriband Inc. Quarterly Report Highlights Strong Cash Position and Strategic Progress Toward NDA Filing for AVERSA Fentanyl in 2025

ORLANDO, FL / ACCESSWIRE / September 4, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) reported financial results for the second quarter ended July 31, 2024. The company reported a strong cash position at the end of the quarter, bolstering its ability to advance the development of its lead product, AVERSA Fentanyl, with an NDA filing targeted for the first half of 2025.

Nutriband is expanding its kinesiology tape contract manufacturing services through its Pocono Pharma subsidiary, with a focus on penetration pricing to gain traction with some of the industry’s largest brands, including KT Tape and Fit For Life Group. Products are being rolled out to prominent retail locations nationwide, including Target, Walmart, Walgreens and CVS.